Cargando…

Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity

An anti-CD30 antibody-drug conjugate incorporating the antimitotic agent DM1 and a stable SMCC linker, anti-CD30-MCC-DM1, was generated as a new antitumor drug candidate for CD30-positive hematological malignancies. Here, the in vitro and in vivo pharmacologic activities of anti-CD30-MCC-DM1 (also k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Yijun, Yang, Tong, Cao, Xuemei, Zhang, Yifan, Zhao, Li, Li, Hua, Zhao, Teng, Xu, Jun, Zhang, Hengbin, Guo, Qingsong, Cai, Junli, Gao, Bei, Yu, Helin, Yin, Sicheng, Song, Ruiwen, Wu, Jingsong, Guan, Lingyu, Wu, Guanghao, Jin, Li, Su, Yong, Liu, Yanjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748589/ https://www.ncbi.nlm.nih.gov/pubmed/31161871 http://dx.doi.org/10.1080/19420862.2019.1618674

Ejemplares similares

Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies
por: Li, Hong, et al.
Publicado: (2017)

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
por: Bartlett, Nancy L, et al.
Publicado: (2014)

CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin
por: Lobastova, Liudmila, et al.
Publicado: (2021)

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
por: Wang, D., et al.
Publicado: (2020)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Characterization of CD30/CD30L(+) Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis
por: Barbieri, Alessandro, et al.
Publicado: (2015)

Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
por: Tschernia, Nicholas P, et al.
Publicado: (2023)

Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma
por: Wang, Guan-Nan, et al.
Publicado: (2017)

A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb
por: Wu, Yang, et al.
Publicado: (2021)

CD30(+) lymphomatoid skin toxicity secondary to ipilimumab
por: Bush, Amelia E., et al.
Publicado: (2020)

Skin CD30(+) T cells and circulating levels of soluble CD30 are increased in patients with graft versus host disease
por: Amedei, Amedeo, et al.
Publicado: (2013)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
por: Xue, YuanBo, et al.
Publicado: (2021)

Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma
por: Sang, Wei, et al.
Publicado: (2022)

Diffuse skin hyperpigmentation in CD30+ lymphoproliferation
por: Prka, Zeljko, et al.
Publicado: (2012)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

High soluble CD30, CD25 and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides
por: Kadin, Marshall E., et al.
Publicado: (2011)

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30(+) tumor cells
por: Reusch, Uwe, et al.
Publicado: (2014)

Elevated ATP via enhanced miRNA-30b, 30c, and 30e downregulates the expression of CD73 in CD8(+) T cells of HIV-infected individuals
por: Shahbaz, Shima, et al.
Publicado: (2022)

Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders
por: Abdulla, Farah R., et al.
Publicado: (2021)

CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection
Publicado: (1994)

Levels of Soluble CD30 and CD26 and Their Clinical Significance in Patients with Primary Immune Thrombocytopenia
por: Wang, Honghui, et al.
Publicado: (2020)

Single-Fraction Radiotherapy for CD30(+) Lymphoproliferative Disorders
por: Gentile, Michelle S., et al.
Publicado: (2015)

Brentuximab vedotin: targeting CD30 as standard in CTCL
por: Prince, H. Miles, et al.
Publicado: (2018)

The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment
por: Dumitru, Adrian Vasile, et al.
Publicado: (2023)

Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells
por: Rajendran, Sakthi, et al.
Publicado: (2019)

TB granuloma: CD30 co-stimulation for CD4(+) T cell co-operation
por: Gress, Abigail R., et al.
Publicado: (2023)

CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro
por: Hansen, Hinrich P., et al.
Publicado: (2016)

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity
por: Zhang, Shangkun, et al.
Publicado: (2022)

Follicular Dendritic Cell Sarcoma With Co-Expression of CD4 and CD30 Mimics Anaplastic Large Cell Lymphoma
por: Liu, Hui, et al.
Publicado: (2020)

Global burden of hematologic malignancies and evolution patterns over the past 30 years
por: Zhang, Nan, et al.
Publicado: (2023)

Study of the expression of CD30 in pterygia compared to healthy conjunctivas
por: Garfias, Yonathan, et al.
Publicado: (2009)

Challenges of driving CD30-directed CAR-T cells to the clinic
por: Grover, Natalie S., et al.
Publicado: (2019)

Better method for detection of CD30: Immunohistochemistry or flow cytometry?
por: Higashi, Morihiro, et al.
Publicado: (2021)

CD3+, CD56+, CD4−, CD8−, CD20−, CD30− Peripheral T-Cell Non-Hodgkin's Lymphoma: A Rare Case Report
por: Jagati, Ashish, et al.
Publicado: (2017)

A novel enediyne‐integrated antibody–drug conjugate shows promising antitumor efficacy against CD30(+) lymphomas
por: Wang, Rong, et al.
Publicado: (2018)

Brentuximab vedotin exerts profound antiproliferative and pro‐apoptotic efficacy in CD30‐positive as well as cocultured CD30‐negative germ cell tumour cell lines
por: Schönberger, Stefan, et al.
Publicado: (2017)

CD153/CD30 signaling promotes age-dependent tertiary lymphoid tissue expansion and kidney injury
por: Sato, Yuki, et al.
Publicado: (2022)

CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases
por: Xu, Jie, et al.
Publicado: (2017)

The short-chain fatty acid acetate coordinates with CD30 to modulate T-cell survival
por: Lyu, Junfang, et al.
Publicado: (2023)

Utilizing CD30 expression as a rational target for therapy of lymphoma
por: Kim, Won Seog
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7d6rb6515e2in5itjknf3fd7a6